PSPhilip Strandwitz

Philip Strandwitz

*This is an algorithmically generated author record based on publicly available information.

Philip Strandwitz has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metabolic engineering of Escherichia coli to modulate hydrogen sulfide levels in the mammalian gut

    by Justin A. Hayes, Brent Buchinger, Anna W. Lunger, Tanvi Khanvilkar, William Gasparrini, Matthew T. Fernez, Madeleine Morrissette, Philip Strandwitz, Abigail N. Koppes, Ryan Koppes, et al.

    Hydrogen sulfide (H 2 S) is a microbiota-derived metabolite in the gastrointestinal tract implicated in a number of diseases. Its volatility and reactivity make experimentally controlling H 2 S concentration in vivo difficult, limiting our ability to interrogate its dose-dependent effects on host physiology. Engineered bacteria present a compelling solution, yet most probiotic metabolic engineering approaches have focused on in vitro optimization, failing to account for the complex intestinal environment. Here, we engineered Escherichia coli strains to produce or consume H 2 S in specific intestinal regions by incorporating knowledge of the local metabolic environment and resident microbial activities into the design process. Analysis of human-derived ex vivo cultures revealed that glutathione (GSH) is inefficiently converted to H 2 S, suggesting GSH as a relatively stable substrate for engineered sulfide production. We thus engineered a GSH-dependent H 2 S producer, which increased levels 21-fold ex vivo . To target the nutrient-rich, microbially sparse environment of the small intestine, we optimized a H 2 S producer that uses L-cysteine as a sulfur source, demonstrating a 7-fold increase in H 2 S levels in mice. Finally, to develop strains capable of sequestering H 2 S, we leveraged the availability of fumarate and nitrate as electron acceptors in the large intestine by engineering a strain expressing sulfide:quinone oxidoreductase (Sqr). This enables oxidation of H 2 S to intracellular polysulfides and achieves higher consumption rates than alternative sequestration strategies reliant on resource-intensive GSH production. Together, this work developed engineered microbes as precision tools to modulate H 2 S levels and showcases a generalizable framework for region-targeted design of engineered probiotics.

  • Open Access

    A human-derived Bacteroides strain attenuates depressive-like behavior in a rat model of social defeat-induced stress

    by Marisol I. Dothard, Mariaelena Caboni, Daniel Norment, Nolan Sigmund, Sarah M. Allard, Jack A. Gilbert, Ekaterina Gavrish, Gabriel Al-Ghalith, Andre Der-Avakian, Philip Strandwitz

    The gut microbiome has been linked to mood disorders via communication along the gut-brain axis. We previously found levels of fecal Bacteroides were inver


  • Open Access

    Cranberry extracts promote growth of Bacteroidaceae and decrease abundance of Enterobacteriaceae in a human gut simulator model

    by Kathleen O'Connor, Madeleine Morrissette, Philip Strandwitz, Meghan Ghiglieri, Mariaelena Caboni, Haiyan Liu, Christina Khoo, Anthony D'Onofrio, Kim Lewis

    The opportunistic pathogen Escherichia coli, a common member of the human gut microbiota belonging to the Enterobacteriaceae family, is the causative agent of the majority of urinary tract infections (UTIs). The gut microbiota serves as a reservoir for uropathogenic E. coli where they are shed in feces, colonize the periurethral area, and infect the urinary tract. Currently, front line treatment for UTIs consists of oral antibiotics, but the rise of antibiotic resistance is leading to higher rates of recurrence, and antibiotics cause collateral damage to other members of the gut microbiota. It is commonly believed that incorporation of the American cranberry, Vaccinium macrocarpon, into the diet is useful for reducing recurrence of UTIs. We hypothesized such a benefit might be explained by a prebiotic or antimicrobial effect on the gut microbiota. As such, we tested cranberry extracts and whole cranberry powder on a human gut microbiome-derived community in a gut simulator and found that cranberry components broadly modulate the microbiota by reducing the abundance of Enterobacteriaceae and increasing the abundance of Bacteroidaceae. To identify the specific compounds responsible for this, we tested a panel of compounds isolated from cranberries for activity against E. coli, and found that salicylate exhibited antimicrobial activity against both laboratory E. coli and human UTI E. coli isolates. In a gut simulator, salicylate reduced levels of Enterobacteriaceae and elevated Bacteroidaceae in a dose dependent manner.


  • Microbes make metabolic mischief by targeting drugs

    by Kim Lewis, Philip Strandwitz


  • Top Cited Papers

    GABA-modulating bacteria of the human gut microbiota

    by Philip Strandwitz, Ki Hyun Kim, Darya Terekhova, Joanne K. Liu, Anukriti Sharma, Jennifer Levering, Daniel McDonald, David Dietrich, Timothy R. Ramadhar, Asama Lekbua, et al.

    The gut microbiota affects many important host functions, including the immune response and the nervous system1. However, while substantial progress has been made in growing diverse microorganisms of the microbiota2, 23-65% of species residing in the human gut remain uncultured3,4, which is an obstacle for understanding their biological roles. A likely reason for this unculturability is the absence in artificial media of key growth factors that are provided by neighbouring bacteria in situ5,6. In the present study, we used co-culture to isolate KLE1738, which required the presence of Bacteroides fragilis to grow. Bioassay-driven purification of B. fragilis supernatant led to the isolation of the growth factor, which, surprisingly, is the major inhibitory neurotransmitter GABA (γ-aminobutyric acid). GABA was the only tested nutrient that supported the growth of KLE1738, and a genome analysis supported a GABA-dependent metabolism mechanism. Using growth of KLE1738 as an indicator, we isolated a variety of GABA-producing bacteria, and found that Bacteroides ssp. produced large quantities of GABA. Genome-based metabolic modelling of the human gut microbiota revealed multiple genera with the predicted capability to produce or consume GABA. A transcriptome analysis of human stool samples from healthy individuals showed that GABA-producing pathways are actively expressed by Bacteroides, Parabacteroides and Escherichia species. By coupling 16S ribosmal RNA sequencing with functional magentic resonance imaging in patients with major depressive disorder, a disease associated with an altered GABA-mediated response, we found that the relative abundance levels of faecal Bacteroides are negatively correlated with brain signatures associated with depression.


  • Top Cited Papers

    Neurotransmitter modulation by the gut microbiota

    by Philip Strandwitz


  • Open Access

    Quinones are growth factors for the human gut microbiota

    by Kathrin Fenn, Philip Strandwitz, Eric J. Stewart, Eric Dimise, Sarah Rubin, Shreya Gurubacharya, Jon Clardy, Kim Lewis

    The human gut microbiome has been linked to numerous components of health and disease. However, approximately 25% of the bacterial species in the gut remain uncultured, which limits our ability to properly understand, and exploit, the human microbiome. Previously, we found that growing environmental bacteria in situ in a diffusion chamber enables growth of uncultured species, suggesting the existence of growth factors in the natural environment not found in traditional cultivation media. One source of growth factors proved to be neighboring bacteria, and by using co-culture, we isolated previously uncultured organisms from the marine environment and identified siderophores as a major class of bacterial growth factors. Here, we employ similar co-culture techniques to grow bacteria from the human gut microbiome and identify novel growth factors. By testing dependence of slow-growing colonies on faster-growing neighboring bacteria in a co-culture assay, eight taxonomically diverse pairs of bacteria were identified, in which an “induced” isolate formed a gradient of growth around a cultivatable “helper.” This set included two novel species Faecalibacterium sp. KLE1255—belonging to the anti-inflammatory Faecalibacterium genus—and Sutterella sp. KLE1607. While multiple helper strains were identified, Escherichia coli was also capable of promoting growth of all induced isolates. Screening a knockout library of E. coli showed that a menaquinone biosynthesis pathway was required for growth induction of Faecalibacterium sp. KLE1255 and other induced isolates. Purified menaquinones induced growth of 7/8 of the isolated strains, quinone specificity profiles for individual bacteria were identified, and genome analysis suggests an incomplete menaquinone biosynthetic capability yet the presence of anaerobic terminal reductases in the induced strains, indicating an ability to respire anaerobically. Our data show that menaquinones are a major class of growth factors for bacteria from the human gut microbiome. These organisms are taxonomically diverse, including members of the genus Faecalibacterium, Bacteroides, Bilophila, Gordonibacter, and Sutterella. This suggests that loss of quinone biosynthesis happened independently in many lineages of the human microbiota. Quinones can be used to improve existing bacterial growth media or modulate the human gut microbiota by encouraging the growth of important symbionts, such as Faecalibacterium species.


  • Antibiotics right under our nose

    by Kim Lewis, Philip Strandwitz